Basel, Basel, Switzerland
Leading the Neural Signalling Section and its labs in Neuroscience and Rare Diseases Research at pRED in Basel. We aim for a patient–centric understanding of disease mechanisms in order to innovate novel therapies for AD, PD and certain rare disorders of the nervous system. I am receiving quite a bit of request to connect, recently. I am happy to accept your request but only if I know you or if you tell me briefly, why you want to connect.
Scientist, Research Project Leader, and Lab Head for drug discovery programs in the area of Alzheimer's and Parkinson's disease. Developing translational biomarker strategies and approaches and supporting clinical development programs. Experienced mentor and people leader.
We explore signalling mechanisms which occur in the context of environment and extracellular cues or to intrinsic changes due to stress (e.g., aging) or certain genetic predisposition (e.g., SNPs, Mendelian forms of neurodegeneration). The section will have a major focus on intracellular pathomechanisms related to proteotoxicity or protein loss-of-function, specific protein-degradation pathways, triggering certain pathways/kinases, and RNA mechanisms in neurons and glia.
Project Leader and Lab Head in preclinical drug and biomarker discovery for age-related neurodegenerative and neuro-immune related disorders; Research Lead in a drug development program for Parkinson's disease
I was instructor (PhD) at the Stanford University, California, in the lab of Prof. Tony Wyss-Coray (http://www.stanford.edu/group/twclab/). The lab focuses on molecular and immunological mechanisms in the brain during health, aging, and chronic degenerative processes.
Research on interactions of immune with nervous system in aging and Alzheimer's disease
Thesis on how drug-specific T cells regulate pathomechanisms of drug-induced delayed-type hypersensitivity reactions/allergies with special interest on skin eruptions and nephritis.